HUTCHMED (NASDAQ:HCM) Raised to Buy at Wall Street Zen

HUTCHMED (NASDAQ:HCM) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also recently issued reports on HCM. Weiss Ratings reiterated a “hold (c)” rating on shares of HUTCHMED in a research report on Wednesday, October 8th. Morgan Stanley cut HUTCHMED from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $18.00 to $13.75 in a research report on Monday, September 22nd. Bank of America lifted their price target on HUTCHMED from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, July 22nd. Finally, Zacks Research cut HUTCHMED from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 9th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, HUTCHMED presently has a consensus rating of “Hold” and a consensus price target of $20.88.

HUTCHMED Stock Down 5.9%

Shares of HCM stock opened at $15.08 on Friday. HUTCHMED has a 1 year low of $11.51 and a 1 year high of $21.50. The business’s fifty day moving average is $16.11 and its 200-day moving average is $15.49. The company has a current ratio of 4.65, a quick ratio of 4.51 and a debt-to-equity ratio of 0.05.

Institutional Investors Weigh In On HUTCHMED

Large investors have recently modified their holdings of the stock. Summit Trail Advisors LLC boosted its stake in shares of HUTCHMED by 7.7% during the 1st quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company’s stock worth $212,000 after acquiring an additional 1,004 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its stake in shares of HUTCHMED by 23.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock worth $233,000 after acquiring an additional 2,916 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares in the last quarter. Vident Advisory LLC boosted its position in shares of HUTCHMED by 78.3% in the first quarter. Vident Advisory LLC now owns 19,728 shares of the company’s stock worth $297,000 after buying an additional 8,664 shares during the period. Finally, Bank of America Corp DE boosted its position in shares of HUTCHMED by 17.3% in the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after buying an additional 3,035 shares during the period. 8.82% of the stock is owned by institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.